These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 15465194

  • 1. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):777-87. PubMed ID: 15465194
    [Abstract] [Full Text] [Related]

  • 2. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S, Kannan V, Deshpande S, Anand V, Ghadi Y.
    J Cancer Res Ther; 2010 Nov 01; 6(1):58-64. PubMed ID: 20479549
    [Abstract] [Full Text] [Related]

  • 3. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1019-34. PubMed ID: 15752881
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):1124-9. PubMed ID: 18313526
    [Abstract] [Full Text] [Related]

  • 6. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N, Azria D, Thézenas S, Barbier N, Fenoglietto P, Delard R, Hay MH, Dubois JB.
    Cancer Radiother; 2004 Apr 01; 8(2):59-69. PubMed ID: 15063872
    [Abstract] [Full Text] [Related]

  • 9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 10. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
    Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G.
    Radiother Oncol; 2007 Aug 01; 84(2):156-63. PubMed ID: 17692976
    [Abstract] [Full Text] [Related]

  • 11. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.
    Int J Radiat Oncol Biol Phys; 2010 Nov 01; 78(3):763-72. PubMed ID: 20171807
    [Abstract] [Full Text] [Related]

  • 12. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):735-42. PubMed ID: 14967428
    [Abstract] [Full Text] [Related]

  • 13. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ, Weltman E, Hanriot RM, Luz FP, Cecílio PJ, da Cruz JC, Moreira FR, Santos AS, Martins LC, Nadalin W.
    Radiat Oncol; 2007 Jan 15; 2():6. PubMed ID: 17224072
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S, Saracino B, Petrongari MG, Gomellini S, Marzi S, Landoni V, Gallucci M, Sperduti I, Arcangeli G.
    Radiother Oncol; 2007 Aug 15; 84(2):148-55. PubMed ID: 17692416
    [Abstract] [Full Text] [Related]

  • 16. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):39-45. PubMed ID: 18538488
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA, Willoughby TR.
    Cancer J; 2001 Jan 01; 7(5):421-6. PubMed ID: 11693901
    [Abstract] [Full Text] [Related]

  • 19. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e415-21. PubMed ID: 21477939
    [Abstract] [Full Text] [Related]

  • 20. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL.
    Int J Radiat Oncol Biol Phys; 2012 Jan 01; 82(1):235-41. PubMed ID: 21163587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.